Literaturverzeichnis


Achard C, Thiers J: Le virilisme pilaire et son association a l insufficiance glycotique (diabetes des femmes a barbe). Bull Acad Nat Med 1921; 86: 51-64

Amato P, Simpson JL: The genetics of polycystic ovary syndrome. Best Practice and Research Clinical Obstetrics and Gynecology 2004; 18 (5): 707-718


Ciampelli M, Fulghesu AM, Cucinelli F et al.: Heterogenity in cell activity, hepatic insulin clearence and peripheral insulin sensitivity in women with PCOS. Hum Reprod 1997, 12: 1897-1901

Ciampelli M, Fulghesu AM, Cucinelli F et al.: Impact of insulin and body mass index on metabolic and endocrine variables in PCOS. Metabolism 1999; 48: 167-172


Dahlgren E, LandinK, Krotkiewski M et al.: Effects of two antiandrogen treatments on hirsutism in women with polycystic ovary syndrome. Hum Reprod 1998; 10: 2706-2711


Diamanti-Kandarakis E, Kolui C, Alexandraki K et al.: Failure of mathematical indices to accurately assess insulin resistance in lean, overweight or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 1273-1276


Erdem NT, Ercan ME, Akyolcu MC et al.: Plasma viscosity as an early cardiovascular risk factor in hirsute women with eumenorrhea or oligomenorrhea. Fert Steril 2003; 80: 1195-1198

Fahri J, Soule S, Jacobs HS: Effect of laparoscopic ovarian electrocautery on ovarian response and outcome treatment with gonadotrophins in clomiphene resistant patients with PCOS. Fert Steril 1995; 64: 930-935


Farquhar CM, Lee O, Toomath R et al.: Spironolactone versus placebo or in combination with steroids for hirsutism and / or acne. Cochrane Database of Systematic Reviews 2003, 4: CD000194


Fenkci V, Fenkci S, Yilmazer M et al.: Decreased total antioxidant status and increased oxidative stress in women with PCOS may contribute to the risk of cardiovascular disease. Fert Steril 2003; 80 : 123-127


Fraser IS, Kovacs G: Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome. Best Practice and Research Clinical Obstetrics and Gynecology 2004; 18 (5): 813-823


Glueck CJ, Wang P, Fontaine R et al.: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrhoeic women with the polycystic ovary syndrome. Metabolism 1999; 48: 511-519


Gjonnaess H: Late endocrine effects of ovarian electrocautery in women with PCOS. Fert Steril 1998; 69: 697-701


Greenblatt E, Caspar RF: Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate. Fert Steril 1993; 60: 766-770


Homburg R: Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome. Best Practice and Research Clinical Obstetrics and Gynecology 2004; 18 (5): 773-788


Jakubowicz DJ, Iuorno MJ, Jakubowicz S et al.: Effects of Metformin on early pregnancy loss in the PCOS. J Clin Endocrinol Metabol 2002; 87: 524-529


Kirchengast S, Huber J: Body composition characteristics and body fat distribution in lean women with PCOS. Hum Reprod 2001; 16: 1255-1260


Lord JM, Flight IH, Norman RJ: Insulin sensitizing drugs (Metformin, trogliazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2003; 3: CD003053


Muth S, Norman J, Sattar N et al.: Women with polycystic ovary syndrome (PCOS) often undergo protracted treatment with metformin and are disinclined: indications for a change in licensing arrangements? Hum Reprod 2004, 12, 2718-2720


Raudrant D, Rabe T: Progesterons with antiandrogenic properties. Drugs 2003; 63: 463-492


Rosenfield RL, Barnes RB, Cara JF et al.: Dysregulation of cytochrom P450 c17α as the cause of PCOS. Fert Steril 1990; 53 (5): 785-791


Stadtmauer LA, Toma SK, Riehl RM et al.: Metformin treatment of patients with PCOS undergoing in vitro fertilisation improves outcomes and is associated with modulation of the insulin-like growth factors. Fert Steril 2001; 75: 505-509


Taylor AE, McCourt B, Martin K et al.: Determinants of abnormal gonadotropin secretion in clinically defined women with PCOS. J Clin Endocrinol Metabol 1997; 82: 2248-2256

Van Der Meer M, Hompes PGA, de Boer J et al.: Cohort size rather than follicle-stimulating hormone threshold levels determines ovarian sensitivity in PCOS. J Clin Endocrinol Metabol 1998; 83: 423-426

Vandermolen DT, Retts VS, Evans WS et al.: Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients withs PCOS who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75: 310-315


Vrbikova J, Bendlova B, Martin H et al.: Insulin sensitivity and β-cell function in women with PCOS. Diabetes Care 2002; 25: 1217-1222


Ying T, Liangzhi X, Taixiang W et al.: Laparoscopic ovarian diathermy versus metformin for women with polycystic ovarian syndrome (Protocol). Cochrane Database of Systematic Reviews 2006; 4: CD006223